Michael Schrag

1.3k citations

20 papers · 779 indexed · h-index 14

Impact in

Pharmacology top 0.5%
- Pharmacogenetics and Drug Metabolism
- Inflammatory mediators and NSAID effects
- Drug-Induced Hepatotoxicity and Protection
Oncology top 10%
- Drug Transport and Resistance Mechanisms
- Cancer Treatment and Pharmacology

Papers in ⓘ

Pharmacology 12
- Pharmacogenetics and Drug Metabolism 12
Oncology 11
- Drug Transport and Resistance Mechanisms 8
- Cancer Treatment and Pharmacology 2

Co-authors: Larry C. Wienkers (6 shared papers)Magang Shou (4 shared papers)Bennett Ma (3 shared papers)William M. Atkins (1 shared paper)Michael J. Dabrowski (1 shared paper)David C. Dale (1 shared paper)Gurkamal Chatta (1 shared paper)A. David Rodrigues (2 shared papers)
Journals: Drug Metabolism and Disposition (7 papers)Bioorganic & Medicinal Chemistry Letters (3 papers)Archives of Biochemistry and Biophysics (2 papers)Clinical Cancer Research (1 paper)Journal of Pharmacology and Experimental Therapeutics (1 paper)
Partner nations: United States China South Africa

In The Last Decade

Michael Schrag

20 papers receiving 749 citations

Peers

Countries citing papers authored by Michael Schrag

Since Specialization

Citations

This map shows the geographic impact of Michael Schrag's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Schrag with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Schrag more than expected).

Fields of papers citing papers by Michael Schrag

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Schrag. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Schrag. The network helps show where Michael Schrag may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael Schrag, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Schrag Line = papers co-authored together Michael Schrag links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Hematopoietic Progenitors and Aging: Alterations in Granulocytic Precursors and Responsiveness to Recombinant Human G-CSF, GM-CSF, and IL-3 Journal of Gerontology ·Gurkamal Chatta, R. G. Andrews, Elin Rodger, Michael Schrag, William P. Hammond, David C. Dale	1993	96
2	MECHANISM-BASED INHIBITION OF HUMAN LIVER MICROSOMAL CYTOCHROME P450 1A2 BY ZILEUTON, A 5-LIPOXYGENASE INHIBITOR Drug Metabolism and Disposition ·Ping Lü, Michael Schrag, Donald E. Slaughter, Conrad E. Raab, Magang Shou, A. David Rodrigues	2003	86
3	A Refined 3-Dimensional QSAR of Cytochrome P450 2C9: Computational Predictions of Drug Interactions Journal of Medicinal Chemistry ·Sreedhara V. Rao, Ron Aoyama, Michael Schrag, William Trager, Allan E. Rettie, Jeffrey P. Jones	2000	75
4	Pyrene·Pyrene Complexes at the Active Site of Cytochrome P450 3A4: Evidence for a Multiple Substrate Binding Site Journal of the American Chemical Society ·Michael J. Dabrowski, Michael Schrag, Larry C. Wienkers, William M. Atkins	2002	75
5	Covalent Alteration of the CYP3A4 Active Site: Evidence for Multiple Substrate Binding Domains Archives of Biochemistry and Biophysics ·Michael Schrag, Larry C. Wienkers	2001	67
6	Triazolam Substrate Inhibition Advances in experimental medicine and biology ·Michael Schrag, Larry C. Wienkers	2001	55
7	Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer Clinical Cancer Research ·Lipika Goyal, Cynthia A. Sirard, Michael Schrag, Michael H. Kagey, Jennifer R. Eads, Stacey Stein, Anthony B. El-Khoueiry, Gulam A. Manji, Thomas A. Abrams, Alok A. Khorana, Rebecca A. Miksad, Devalingam Mahalingam, Andrew X. Zhu, Dan G. Duda	2020	46
8	SULFOTRANSFERASE 1E1 IS A LOW KM ISOFORM MEDIATING THE 3-O-SULFATION OF ETHINYL ESTRADIOL Drug Metabolism and Disposition ·Michael Schrag, Donghui Cui, Thomas H. Rushmore, Magang Shou, Bennett Ma, A. David Rodrigues	2004	45
9	Topological Alteration of the CYP3A4 Active Site by the Divalent Cation Mg2+ Drug Metabolism and Disposition ·Michael Schrag, Larry C. Wienkers	2000	37
10	Mechanism-Based Inactivation of Cytochrome P450 2B1 by 7-Ethynylcoumarin: Verification of Apo-P450 Adduction by Electrospray Ion Trap Mass Spectrometry Chemical Research in Toxicology ·Kelly Regal, Michael Schrag, Ute M. Kent, Larry C. Wienkers, Paul F. Hollenberg	2000	33
11	Catalytic turnover of pyrene by CYP3A4: Evidence that cytochrome b5 directly induces positive cooperativity Archives of Biochemistry and Biophysics ·Monica I. Jushchyshyn, J. Matthew Hutzler, Michael Schrag, Larry C. Wienkers	2005	32
12	Bacterial N-succinyl-L-diaminopimelic acid desuccinylase. Purification, partial characterization, and substrate specificity. Journal of Biological Chemistry ·Y K Lin, R. Myhrman, Michael Schrag, Michael H. Gelb	1988	32
13	SOLVENT EFFECT ON cDNA-EXPRESSED HUMAN SULFOTRANSFERASE (SULT) ACTIVITIES IN VITRO Drug Metabolism and Disposition ·Bennett Ma, Magang Shou, Michael Schrag	2003	30
14	Benzodiazepine Binding Site Occupancy by the Novel GABAA Receptor Subtype-Selective Drug 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in Rats, Primates, and Humans Journal of Pharmacology and Experimental Therapeutics ·John Atack, Dean F. Wong, Tim D. Fryer, Christine Ryan, Sandra Sanabria, Yun Zhou, Robert F. Dannals, Wai-si Eng, Raymond E. Gibson, H. Donald Burns, José M. Vega, Laura Vessy, Paul Scott‐Stevens, John S. Beech, Jean‐Claude Baron, Bindi Sohal, Michael Schrag, Franklin I. Aigbirhio, Ruth M. McKernan, Richard Hargreaves	2009	27
15	Discovery of amido-benzisoxazoles as potent c-Kit inhibitors Bioorganic & Medicinal Chemistry Letters ·Roxanne K. Kunz, Shannon Rumfelt, Ning Chen, Dawei Zhang, Andrew S. Tasker, Roland W. Bürli, Randall W. Hungate, Violeta Yu, Yen Nguyen, Douglas A. Whittington, Kristin L. Meagher, Matthew Plant, Yanyan Tudor, Michael Schrag, Yang Xu, Gordon Ng, Essa Hu	2008	10
16	Novel 5- and 6-subtituted benzothiazoles with improved physicochemical properties: Potent S1P1 agonists with in vivo lymphocyte-depleting activity Bioorganic & Medicinal Chemistry Letters ·Mike Frohn, Victor J. Cee, Brian A. Lanman, Alexander J. Pickrell, Jennifer E. Golden, Dalia Rivenzon‐Segal, Scot Middleton, Mike Fiorino, Han Xu, Michael Schrag, Yang Xu, Michele McElvain, Kristine Muller, Jerry Siu, Roland W. Bürli	2011	9
17	Structural Characterization of Novel Adenine Dinucleotide Phosphate Conjugates of Imatinib in Incubations with Rat and Human Liver Microsomes Drug Metabolism and Disposition ·Shuguang Ma, Raju Subramanian, Xu Yang, Michael Schrag, Magang Shou	2008	7
18	CYTOCHROME P450 2C8 (CYP2C8)-MEDIATED HYDROXYLATION OF AN ENDOTHELIN ETA RECEPTOR ANTAGONIST IN HUMAN LIVER MICROSOMES Drug Metabolism and Disposition ·Bennett Ma, Raju Subramanian, Michael Schrag, A. David Rodrigues, Cuyue Tang	2004	7
19	Discovery of a potent and selective c-Kit inhibitor for the treatment of inflammatory diseases Bioorganic & Medicinal Chemistry Letters ·Ning Chen, Roland W. Bürli, Susana Neira, Randall W. Hungate, Dawei Zhang, Violeta Yu, Yen Nguyen, Yanyan Tudor, Matthew Plant, Shaun Flynn, Kristin L. Meagher, Matthew R. Lee, Xuxia Zhang, Andrea Itano, Michael Schrag, Yang Xu, Gordon Ng, Essa Hu	2008	6
20	HETEROTROPIC MODULATION OF SULFOTRANSFERASE 2A1 ACTIVITY BY CELECOXIB: PRODUCT RATIO SWITCHING OF ETHYNYLESTRADIOL SULFATION Drug Metabolism and Disposition ·Donghui Cui, Catherine Booth-Genthe, Edward J. Carlini, Brian Carr, Michael Schrag	2004	4

About Michael Schrag

Michael Schrag is a scholar working on Pharmacology, Oncology, Molecular Biology, Spectroscopy and Genetics, having authored 20 papers that have together received 779 indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (12 papers), Drug Transport and Resistance Mechanisms (8 papers), Analytical Chemistry and Chromatography (4 papers), Cancer Treatment and Pharmacology (2 papers), Chronic Lymphocytic Leukemia Research (2 papers), Chronic Myeloid Leukemia Treatments (2 papers), Mast cells and histamine (1 paper) and Quinazolinone synthesis and applications (1 paper). The work is most often cited by research in Pharmacology (423 citations), Oncology (270 citations), Computational Theory and Mathematics (139 citations), Spectroscopy (97 citations) and Biochemistry (37 citations). Michael Schrag has collaborated with scholars based in United States, China and South Africa. Frequent co-authors include Larry C. Wienkers, Magang Shou, Bennett Ma, William M. Atkins, Michael J. Dabrowski, David C. Dale, Gurkamal Chatta, A. David Rodrigues, Elin Rodger and William P. Hammond. Their work appears in journals such as Drug Metabolism and Disposition, Bioorganic & Medicinal Chemistry Letters, Archives of Biochemistry and Biophysics, Clinical Cancer Research and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact